Metastatic prostate cancer with normal level of serum prostate-specific antigen

被引：32

作者：

R. Nishio

Y. Furuya

O. Nagakawa

H. Fuse

机构：

[1] Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama 930-0194

来源：

International Urology and Nephrology | 2003年 / 35卷 / 2期

关键词：

Low PSA; Metastasis; Prostate cancer;

D O I：

10.1023/B:UROL.0000020306.08275.49

中图分类号：

学科分类号：

摘要：

The clinical and pathological features of metastatic prostate cancer with normal level of serum prostate-specific antigen (PSA) were investigated. Four patients with metastatic prostate cancer had serum PSA within the normal range at the diagnosis. All tumors were poorly-differentiated adenocarcinoma. Endocrine therapy was performed as the initial therapy in all patients. Despite subsequently treatment, all cases died of prostate cancer at 2, 8, 9 and 38 months. During disease progression, 3 of 4 patients had elevated serum markers such as carcinoembryonic antigen (CEA), CA19-9, CA15-3, CA125, neuron-specific enolase and pro-gastrin releasing peptide. Immunohistochemical examination of the initial biopsy specimens revealed that 4 and 3 cases were positive for CEA and chromogranin A, respectively. In advanced prostate cancer patients with low PSA level, those markers may aid in the follow up of disease. © 2004 Kluwer Academic Publishers.

引用

页码：189 / 192

页数：3

共 14 条

[1]

Cooner W.H., Mosley B.R., Rutherford C.L., Beard J.H., Pond H.S., Bass R.B., Terry W.J., Igel T.C., Kidd D.D., Prostate cancer detection in a clonical urological practice by ultrasonography, digital rectal examination and prostate specific antigen, J. Urol., 143, (1990)

[2]

Stamey T.A., Kabalin J.N., Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients, J. Urol., 141, (1989)

[3]

Cohen R.J., Haffejee Z., Steele G.S., Nayler S.J., Advanced prostate cancer with normal serum prostate-specific antigen values, Arch. Pathol. Lab. Med., 118, (1994)

[4]

Sella A., Konichezky M., Flex D., Sulkes A., Baniel J., Low PSA metastatic androgen-independent prostate cancer, Eur. Urol., 38, (2000)

[5]

Yamamoto S., Ito T., Akiyama A., Aizawa T., Miki M., Tachibana M., M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/ml, Int. J. Urol., 8, (2001)

[6]

General Rule for Clinical and Pathological Studies on Prostate Cancer, (2001)

[7]

Yamaguchi K., Sumiya H., Fuse H., Matsuzaki O., Ito H., Shimazaki J., Androphilic protein studied histochemically in stage D2 prostatic cancer, Cancer, 61, (1988)

[8]

Furuya Y., Cho S., Ohta S., Sato N., Kotake T., Masai M., High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer, J. Urol., 166, (2001)

[9]

Gkonos P.J., Krongrad A., Roos B.A., Neuroendocrine peptides in the prostate, Urol. Res., 23, (1995)

[10]

Kadmon D., Thompson T.C., Lynch G.R., Et al., Elevated Plasma chromogranin A concentrations in prostatic carcinoma, J. Urol., 146, (1991)

← 1 2 →